FDA Approves Vertex Pharma's JOURNAVX As The First Drug In A New Class Of Non-Opioid Pain Medicines
Vertex Pharmaceuticals Inc. (VRTX) has secured FDA approval for Suzetrigine, an oral, non-opioid, highly selective NaV1.8 pain signal ...
Mena FN10d
Global Pain Management Market To Surge From USD 73.24 Billion In 2023 To USD 108.48 Billion By 2032, Reports SNS Insider
Due to their effectiveness, cost-effectiveness, and easy access, they are a favored option for addressing issues such as arthritis and musculoskeletal disorders. NSAIDs remain a key treatment choice ...